Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets. In the historic dot.com year 2000, he trained as a CEFA analyst in Frankfurt and has since then accompanied over 20 IPOs in Germany.
Until 2018, he held various positions at banks as an asset manager, capital market and macro expert as well as fundamental equity analyst. He is passionate about the energy, commodity and technology markets as well as the tactical and strategic asset allocation of liquid investment products. As an expert speaker at investment committee meetings of funds as well as at customer events, he can still describe the course of the 1987 crash, one of the major buying opportunities of the last 33 years on the stock market.
Today, he knows that the profit in shares is not necessarily the result of buying cheaply, but above all of avoiding mistakes and recognizing in good time when markets are ready to let air out. After all, in addition to basic fundamental analysis, investing in stocks is above all a phenomenon of global liquidity and this must be monitored regularly.
Commented by André Will-Laudien
Commented by André Will-Laudien on July 31st, 2025 | 07:15 CEST
AI and biotech – A dream team for returns! Evotec and Novo Nordisk in the spotlight, and NetraMark steps on the gas!
The biotech sector is currently undergoing profound change: big data and artificial intelligence are revolutionizing the way drugs are researched and developed. AI-supported systems help identify molecular target structures more quickly and select active ingredients more precisely. Both start-ups and established companies are increasingly using data-based platforms to shorten development times and make clinical trials more successful. Investors are increasingly directing their capital toward companies that combine biotechnology with modern data analysis. The stock market is ruled by daily madness with figures that are not within the expected range. However, innovative growth markets will remain volatile and attractive at the same time, so bet on the winners!
Read
Commented by André Will-Laudien on July 30th, 2025 | 07:00 CEST
Trump's Tariffs & Takeovers! BioNTech, PanGenomic Health, Pfizer, and Valneva Targeted by Speculators
The US-EU tariff agreement has now been finalized. Many sectors of the European economy will now face additional burdens and margin cuts. The biotech and pharmaceutical industries have been spared, as medicines and active pharmaceutical ingredients are among the few product groups that are traditionally traded duty-free in transatlantic trade. This is due to international agreements, such as the WTO Pharmaceutical Agreement, which both the EU and the US have signed. Clinical trial drugs, active ingredient imports, and vaccines are also mostly exempt from tariffs. Valneva is currently making headlines with its chikungunya vaccine, BioNTech and Pfizer are continuing to sell COVID-19 vaccines on a small scale, and PanGenomic is surprising everyone with a new AI-powered health platform. A lot is going on in the sector – who are the big earners?
Read
Commented by André Will-Laudien on July 29th, 2025 | 07:05 CEST
Trump tariffs settled? What are the triggers now? Palantir, naoo AG, TeamViewer, and D-Wave
With the US-EU agreement on tariffs, markets opened positively yesterday but quickly slipped into negative territory. The reason: the agreement is widely viewed as a "loss-making deal" for the EU. While tariffs of over 20% were averted, 15% still remain. In return, NATO must purchase substantial US military equipment, while US vehicle exports to the EU remain tariff-free. Donald Trump could not have negotiated better himself - a diplomatic failure for Brussels. The decision will have a significant impact on the EU's automotive sector, luxury and consumer goods industries, and technology sector. For example, European wine will cost US consumers about 30% more, factoring in currency losses, which is devastating for European winemakers. All in all, this deal is considered a major setback for free trade, with serious inflationary consequences and declining consumer demand. Investors should reposition themselves, as late summer looks stormy from this perspective alone.
Read
Commented by André Will-Laudien on July 28th, 2025 | 07:25 CEST
Gold and silver rally in 2025 – Panic buying ahead! Silver North, BYD, and VW in the fast lane!
Silver has long since ceased to be gold's little brother! Over the past 12 months, silver has clearly outperformed its big brother, rising 38% compared to a 27% increase in gold. This is due to several factors. Firstly, there are only around 240 active silver mines worldwide, compared to 1,350 gold mines. In recent years, silver has established itself as an industrial metal, as it is in high demand in high-tech, e-mobility, defense, and medical applications. This means that less and less of the coveted metal is left for the investment market, and physical stocks on the futures markets are also declining steadily. The time has therefore come to allocate some of your portfolio to silver, the little brother of gold, which has performed well. Silver explorers and developers offer the greatest leverage. Here are a few ideas.
Read
Commented by André Will-Laudien on July 28th, 2025 | 07:15 CEST
Better than Nvidia and without AI – 185% with Veganz, Bayer, Novo Nordisk, and Nestlé in focus
It does not always have to be NVIDIA. German stocks are also performing well. Those who took advantage of Trump's tariff panic in April to buy in have since earned 75% with NVIDIA, but a whopping 185% with German plant-based nutrition expert, Veganz Group. Even the long-sidelined pharmaceutical giant Bayer has made an astonishing comeback with 50% growth, while Nestlé, supposedly an anchor in many portfolios, has lost 15%. Some call it selection luck, while others refer to it as sector rotation. It is currently apparent that the long, strong rally on international stock markets is benefiting only a few stocks. It remains fascinating that the stock market always celebrates when Donald Trump's tariff threats ultimately turn out to be less severe than initially expected. What remains for the economy, however, is less growth and high prices at the checkout. The new US policy stands for many things, but first and foremost, for less trade and economic downturn. How can investors still profit?
Read
Commented by André Will-Laudien on July 25th, 2025 | 07:05 CEST
Biotech turns to gold: Who is swallowing whom - or what? Evotec, BioNxt, Valneva, and Formycon are on the list!
The biotech sector is closely monitoring central bank interest rates. At present, however, inflation still seems a little too high to expect significant cuts. Accordingly, the European Central Bank left its key interest rates unchanged yesterday. Investors are now looking to Wall Street for signals on where rates might head in the second half of the year. However, due to the sharp price increases on the Nasdaq and existing undervaluations, takeover rumors are starting to circulate - and could materialize at any time. BioNxt, Evotec, and Valneva are on our watchlist. Where do the opportunities lie for investors?
Read
Commented by André Will-Laudien on July 24th, 2025 | 07:15 CEST
Buying frenzy on the NASDAQ – Another 200% with D-Wave, MiMedia, and Super Micro Computer?
New record highs every day – a joy for investors, but a source of stress for fund managers. Time and again in history, stock markets have risen unchecked, only to be followed by an equally unexpected correction. This usually happens when there is a high degree of complacency. One indicator of investor sentiment is the so-called Fear & Greed Index. With values above 75 out of 100, it has been in the "Extreme Greed" zone for weeks now. But as a famous quote from the 1987 movie "Wall Street" said: "Greed is good!" We examine a few stocks with promising prospects and are betting on a continuation of the remarkable rally.
Read
Commented by André Will-Laudien on July 24th, 2025 | 07:00 CEST
What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA
The stock market is currently taking no prisoners. Megatrends such as AI and high-tech have enabled investors to reap substantial returns over the past two years. But for the past three months, defense and armament stocks have been performing a wild dance on the trading floor. With special public programs to upgrade NATO, investors are expecting billions to flow into companies that maintain a defense segment in their business model. But how can a 600% rise in share prices be justified with just 20% more orders? What if DroneShield disappoints in September? The Australian hydrogen specialist Pure Hydrogen is currently expanding into the US, and much remains to be seen here. So where are the opportunities for investors?
Read
Commented by André Will-Laudien on July 23rd, 2025 | 07:25 CEST
After a 500% increase - is the next rocket stage about to launch? Rheinmetall, Almonty, Hensoldt, and Steyr in focus!
Some investors are reluctant to add stocks that have already performed strongly to their portfolios. In general, this is not good advice, as a sharp rise often has fundamental reasons. For example, the Düsseldorf-based defense company Rheinmetall is expected to increase its business volume roughly fivefold in the coming years. However, its share price has already skyrocketed by a factor of 20 since the start of 2022. The second-tier defense stocks have not been able to make the same leap, but some have managed gains of up to 500%. What happens next? Technical analysts often say: "The trend is your friend." This suggests that after a correction, the sun will soon shine again. In the strategic metals sector, Almonty Industries has recently made strong progress, and the rally could continue significantly regardless of defense investments. We have done the math for you.
Read
Commented by André Will-Laudien on July 23rd, 2025 | 07:05 CEST
The hot phase for nuclear energy is beginning! Oklo, First Hydrogen, Nel, Siemens Energy, and Plug Power
For a long time, nuclear power was considered a thing of the past; however, a significant shift in energy policy is now underway worldwide. The US is at the forefront of this movement. Under Donald Trump, a comprehensive action plan to rebuild the nuclear industry was recently adopted. The goal is nothing less than to quadruple the country's nuclear power capacity, in particular through the massive expansion of small modular reactors (SMRs), which are compact, decentralized mini nuclear power plants. They are considered efficient, safe, and scalable. The message is clear: the United States wants to regain its position as the dominant nuclear power, both in terms of energy policy and technology. Which companies are in the spotlight?
Read